David R. Philips
Keine laufenden Positionen mehr
Profil
David R.
Philips is the founder of COR Therapeutics, Inc. (1988), Global Blood Therapeutics, Inc. (2011), and Portola Pharmaceuticals, Inc. (2003).
At Portola Pharmaceuticals, Inc., he held the title of Senior Vice President-Biology from 2003 to 2012.
Dr. Philips also held former positions as a Principal at Millennium Pharmaceuticals, Inc., St. Jude Children's Research Hospital, Inc., and Gladstone Foundation (CA).
He earned a doctorate degree from the University of Southern California and an undergraduate degree from the University of California, Los Angeles.
Ehemalige bekannte Positionen von David R. Philips
| Unternehmen | Position | Ende |
|---|---|---|
| Gladstone Foundation (CA) | Corporate Officer/Principal | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Gründer | - |
St. Jude Children's Research Hospital, Inc.
 St. Jude Children's Research Hospital, Inc. Hospital/Nursing ManagementHealth Services St. Jude Children's Research Hospital, Inc. offers health care and social assistance services for children. It is internationally recognized for its pioneering research and treatment for children with cancer and other catastrophic diseases. The firm's treatment programs include brain tumors, leukemia, lymphoma, infectious diseases, immunodeficiency diseases, blood disorders, sickle cell disease, and solid tumors. The company was founded by Danny Thomas on February 4, 1962 and is headquartered in Memphis, TN. | Corporate Officer/Principal | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Gründer | - |
Ausbildung von David R. Philips
| University of California, Los Angeles | Undergraduate Degree |
| University of Southern California | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
St. Jude Children's Research Hospital, Inc.
St. Jude Children's Research Hospital, Inc. Hospital/Nursing ManagementHealth Services St. Jude Children's Research Hospital, Inc. offers health care and social assistance services for children. It is internationally recognized for its pioneering research and treatment for children with cancer and other catastrophic diseases. The firm's treatment programs include brain tumors, leukemia, lymphoma, infectious diseases, immunodeficiency diseases, blood disorders, sickle cell disease, and solid tumors. The company was founded by Danny Thomas on February 4, 1962 and is headquartered in Memphis, TN. | Health Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
| Gladstone Foundation (CA) |
